26
|
Babić-Naglić D, Anić B, Čikeš N, Novak S, Grazio S, Morović-Vergles J, Kehler T, Marasović-Krstulović D, Milanović S, Hanih M, Perić P, Vlak T, Potokič K, Ćurković B. [The proposal of the Croatian Society for Rheumatology for the treatment of adult rheumatoid arthritis patients with biologics, 2013]. REUMATIZAM 2013; 60:47-51. [PMID: 24003685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Standardized approach to the patients with rheumatoid arthritis (RA) is one of the requirements of good clinical practice. Croatian Society for Rheumatology (HRD) of Croatian Medical Association (HLZ) updated the Proposed treatment of rheumatoid arthritis (RA) with biologic agents in line with recent findings in rheumatology for the last 3 years. By complying with the agreed standards of treatment we can avoid malpractice and irrational consumption, and to the most patients provide a greater chance for a favorable outcome.
Collapse
|
27
|
Morović-Vergles J, Puksić S, Gracanin AG. [Large vessel vasculitides]. REUMATIZAM 2013; 60:35-38. [PMID: 24979994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Large vessel vasculitis includes Giant cell arteritis and Takayasu arteritis. Giant cell arteritis is the most common form of vasculitis affect patients aged 50 years or over. The diagnosis should be considered in older patients who present with new onset of headache, visual disturbance, polymyalgia rheumatica and/or fever unknown cause. Glucocorticoides remain the cornerstone of therapy. Takayasu arteritis is a chronic panarteritis of the aorta ant its major branches presenting commonly in young ages. Although all large arteries can be affected, the aorta, subclavian and carotid arteries are most commonly involved. The most common symptoms included upper extremity claudication, hypertension, pain over the carotid arteries (carotidynia), dizziness and visual disturbances. Early diagnosis and treatment has improved the outcome in patients with TA.
Collapse
|
28
|
Foocharoen C, Tyndall A, Hachulla E, Rosato E, Allanore Y, Farge-Bancel D, Caramaschi P, Airó P, Nikolaevna SM, Pereira da Silva JA, Stamenkovic B, Riemekasten G, Rednic S, Sibilia J, Wiland P, Tarner I, Smith V, Onken AT, Abdel Atty Mohamed WA, Distler O, Morović-Vergles J, Himsel A, de la Peña Lefebvre PG, Hügle T, Walker UA. Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. Arthritis Res Ther 2012; 14:R37. [PMID: 22348608 PMCID: PMC3392836 DOI: 10.1186/ar3748] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2011] [Revised: 12/11/2011] [Accepted: 02/20/2012] [Indexed: 02/05/2023] Open
Abstract
Introduction Erectile dysfunction (ED) is common in men with systemic sclerosis (SSc) but the demographics, risk factors and treatment coverage for ED are not well known. Method This study was carried out prospectively in the multinational EULAR Scleroderma Trial and Research database by amending the electronic data-entry system with the International Index of Erectile Function-5 and items related to ED risk factors and treatment. Centres participating in this EULAR Scleroderma Trial and Research substudy were asked to recruit patients consecutively. Results Of the 130 men studied, only 23 (17.7%) had a normal International Index of Erectile Function-5 score. Thirty-eight per cent of all participants had severe ED (International Index of Erectile Function-5 score ≤ 7). Men with ED were significantly older than subjects without ED (54.8 years vs. 43.3 years, P < 0.001) and more frequently had simultaneous non-SSc-related risk factors such as alcohol consumption. In 82% of SSc patients, the onset of ED was after the manifestation of the first non-Raynaud's symptom (median delay 4.1 years). ED was associated with severe cutaneous, muscular or renal involvement of SSc, elevated pulmonary pressures and restrictive lung disease. ED was treated in only 27.8% of men. The most common treatment was sildenafil, whose efficacy is not established in ED of SSc patients. Conclusions Severe ED is a common and early problem in men with SSc. Physicians should address modifiable risk factors actively. More research into the pathophysiology, longitudinal development, treatment and psychosocial impact of ED is needed.
Collapse
|
29
|
Morović-Vergles J, Mitrović J. [Pathogenesis of polymyositis and dermatomyositis]. REUMATIZAM 2012; 59:23-26. [PMID: 23745450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The idiopathic inflammatory myopathies, collectively called myositis, are a heterogeneous group of diseases of which polymyositis and dermatomyositis are the best known. These heterogeneous group of chronic disordes sharing the clinical symptom of muscle weakness and, in typical cases, inflammatory cell infiltrates in muscle tissue. There are four major types of idiopathic inflammatory myopathies: dermatomyositis, polymyositis, inclusion body myositis and immune-mediated necrotizing myopathies (autoimmune necrotizing myopathies). Clinical and histopatological distinctions between these conditions suggest that different pathogenic processes underline each of the inflammatory myopathies.
Collapse
|
30
|
Morović-Vergles J, Culo MI. [Extra-articular manifestations of seronegative spondyloarthritides]. REUMATIZAM 2011; 58:54-56. [PMID: 22232949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The term seronegative spondyloarthritides (SpA) is used to refer to a family of inflammatory rheumatic diseases characterised by inflammation of axial joints, asymmetric oligoarthritis and enthesitis, sometimes involving nonarticular structures, such as skin, heart, aortic valve, eye and kidney. The SpA consist of the following entities: ankylosing spondylitis, reactive arthritis, psoriatic arthritis, spondyloarthritis associated with IBD and undifferentiated spondyloarthritis. The prevalence of SpA in the population is 0,5-2%.
Collapse
|
31
|
Hadzibegović I, Mitrović J, Santini M, Vukelić D, Morović-Vergles J. [Relapsing polychondritis--case report]. LIJECNICKI VJESNIK 2011; 133:27-30. [PMID: 21644276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Relapsing polychondritis (RP) is a rare systemic inflammatory disease in which recurrent episodes of cartilage inflammation result in destruction of ears, nose and tracheobronchal tract. The joints, eyes, audiovestibular system and cardiovascular system can also be involved. About 30% of patients with RP have coexisting autoimmune disease, or malignant disease like colon, breast, and lung carcinoma, or malignant lymphoma. Pathogenesis is still unknown, and there is no consistent laboratory parameter specific for RP, which makes the diagnosis mainly clinical. Glucocorticoids are a mainstay of medical treatment of RP, whereas newer studies show positive effects of biological therapy. The course of RP is characterized by recurrent episodes of cartilage inflammation, and the prognosis has been recently improved because of improved medical and surgical treatment. We present a case of a patient with RP who was diagnosed 1 month after the development of first symptoms and responded well to glucocorticoid therapy.
Collapse
|
32
|
Morović-Vergles J, Gamulin S. Anti-TNFα therapy and control of chronic pain in ankylosing spondylitis. J Pain Symptom Manage 2010; 40:e9-11. [PMID: 20932711 DOI: 10.1016/j.jpainsymman.2010.08.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2010] [Revised: 08/28/2010] [Accepted: 08/29/2010] [Indexed: 11/20/2022]
|
33
|
Ostović KT, Kaić G, Ostović I, Skoro M, Novak NP, Morović-Vergles J. The importance of urgent cytological examination of synovial fluids in differentiation inflammatory and non-inflammatory joint diseases. COLLEGIUM ANTROPOLOGICUM 2010; 34:145-152. [PMID: 20432743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The aim of this study was to imply the possibilities of the urgent cytological examination of synovial fluids in differential diagnosis of arthropathies and to motivate the clinicians to use this method. It gave valuable information particularly with respect to differentiate the inflammatory and non-inflammatory joint diseases. This study included 115 synovial fluids obtained by fine needle aspiration (FNA) of the swollen knee from the patients in the period between 2003 and 2008. At our department the urgent cytological examination of the synovial fluids consisted of macroscopic analysis that includes volume, colour, clarity, viscosity and mucin clot test, native microscopic analysis for crystals and tissue fragments, counting the total nucleated cell count and semiquantitative microscopic analysis for neutrophil granulocyte percentage on the slides stained with Hemacolor rapid staining. All cytological analyses were done within one hour since FNA. According to our results the clarity, viscosity, mucin clot test, the total nucleated cell count and the neutrophil granulocyte percentage enabled distinction between inflammatory and non-inflammatory diseases with statistically significant difference at the 0.01 level but we could not differentiate these two groups of illnesses according to volume and colour. In inflammation the total nucleated cell count and the neutrophil granulocyte percentage was greater than in non-inflammation, the clarity was only translucent and opaque, the viscosity was low and the mucin clot test was negative. In non-inflammatory diseases the clarity varied from transparent to opaque, the total nucleated cell count and the neutrophil granulocyte percentage was smaller than in inflammatory diseases, the viscosity was high and consequently the mucin test was highly positive in all samples. Crystals were detected in only 12 samples of synovial fluids, mostly in inflammation and they were all monosodium urate (MUS) so we could diagnose gout. We could conclude that the urgent cytological analysis of the synovial fluid is a very useful, simple and reliable basic diagnostic screening test in differentiation inflammatory and non-inflammatory joint diseases and we recommended using it as the initial test in the diagnostic procedure of these illnesses using our protocol.
Collapse
|
34
|
Curković B, Babić-Naglić D, Morović-Vergles J, Anić B, Grazio S, Kaliterna DM, Hanih M, Novak S. [Proposal for biologic drugs therapy in rheumatoid arthritis]. REUMATIZAM 2010; 57:29-35. [PMID: 20941938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Rheumatoid arthritis is a chronic, inflammatory disease with the prevalence about 1%. Rheumatoid arthritis is characterized with synovitis, often evolve erosions of the joints, pain and functional deficit. Etiology is unknown, but the development of such autoimmune disease is due to genetic and environmental factors. Most of the patients with diagnosis of rheumatoid arthritis use nonbiologic disease modifying antirheumatic drugs. Advances in the undersstanding of the disease process have led to the development of biological agents to treat rheumatoid arthritis. With the use of biologic agents we wish to evolve the goal of therapy from that of symptomatiic relief to clinical remission. Biologic drugs have documented, fast and continuous efficacy with generaly well accepted safety profile. On behalf of Croatian Society for Rheumatology we propose recommendations for the biologic therapy in rheumatoid arthritis.
Collapse
|
35
|
Morović-Vergles J, Culo MI, Kaliterna DM. [Scleroderma renal crisis]. REUMATIZAM 2010; 57:109-111. [PMID: 21875014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Systemic sclerosis (SSc) is a multisystem disease whose clinical manifestations result from inflammation, vascular injury and obliteration, and cutaneous and visceral fibrosis. Scleroderma renal crisis (SRC) occurs in 5% of patients with particullary diffuse form of SSc. It is characterized by malignant hypertension and oligo/ anuric acute renal failure. SRC was once a uniformly fatal complication of SSc. The prognosis of SRC has significantly improved with the introduction of angiotensin-converting enzyme inhibitors (ACEi) as treatment. The treatment of SRC relies on tight control of blood pressure and aggressive treatment with ACEi, if needed in combination with other types of antihypertensive drugs.
Collapse
|
36
|
Morović-Vergles J. [Safety of rituximab in patients with rheumatoid arthritis]. REUMATIZAM 2010; 57:158-160. [PMID: 21875022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
RA is a chronic disease and long-term use of treatments that target TNF or B cells will be required for continued disease control. One approach to targeting B cells in RA is the use ofrituximab. It is a genetically engineered chimeric monoclonal antibody that selectively depletes peripheral B lymphocytes by binding CD20 on the cell surface. Long-term safety data show that rituximab treatment is associated with rates of infections and serious infections that remain stable over multiple treatment courses. Also, is associated with rates of malignancy consistent with data from the general RA population and is not associated with an increase in the rate of serious infections in patients who receive subsequent biologic treatment. In conclusion, rituximab is generally safe and well tolerated.
Collapse
|
37
|
Novak S, Morović-Vergles J. [Why do we need registries of patients on biologics drugs?]. REUMATIZAM 2010; 57:151-153. [PMID: 21875019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Significant data on applied biologic drugs can be found in national registries of treated patients. The main reason of establishing registries is monitoring the efficacy and safety of biologic drugs in long-term treatment. Registries provide information on outcome of the disease, life quality, and risk-benefit ratio including society costs.
Collapse
|
38
|
Grazio S, Curković B, Babić-Naglić D, Anić B, Morović-Vergles J, Vlak T, Gnjidić Z, Kaliterna DM, Novak S, Kehler T, Hanih M. [Guidelines of the Croatian Society for Rheumatology for the treatment of knee and hip osteoarthritis]. REUMATIZAM 2010; 57:36-47. [PMID: 20941939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Osteoarthritis of the hip and the knee belongs to one of the most disabiliting conditions. Treatment goals for these patients include a reduction in pain, an improvement in joint mobility and to limit functional impairment. To properly manage osteoarthritis, both nonpharmacologic (non-interventional) and pharmacologic modalities may be employed, while minority of patients will require surgery. According to the available evidence for available therapies and experts' opinion here we present guidelines for the treatment of hip and the knee osteoarthritis in Croatia.
Collapse
|
39
|
Salamon L, Morović-Vergles J. Initial presentation of hereditary angioedema as abdominal pain and ascites in puerperium: case report. ACTA DERMATOVENEROLOGICA CROATICA : ADC 2010; 18:261-263. [PMID: 21251443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Hereditary angioedema is a rare genetic disorder resulting from an inherited deficiency or dysfunction of the C1 inhibitor. It is characterized by recurrent, circumscribed, and self-limiting episodes of cutaneous and mucous membrane swelling involving different organs. Hereditary angioedema may present with diverse clinical pictures, even within families with the same mutation. We present a first reported case of type 1 hereditary angioedema in a young woman presenting as recurrent abdominal pain associated with ascites without any other clinical features of hereditary angioedema, with initial presentation in puerperium. The recognition or awareness of hereditary angioedema as a cause of acute and/or recurrent abdominal pain associated with ascites is important, and may avoid unnecessary invasive procedures and facilitate appropriate treatment.
Collapse
|
40
|
Morović-Vergles J. [Cardiovascular diseases and rheumatoid arthritis]. REUMATIZAM 2010; 57:11-15. [PMID: 21874999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Morbidity and mortality rates are higher in rheumatoid arthritis (RA) patients than in the general population. RA is associated with an increased risk of cardiovascular disease. All of the cardiac structures can be affected during the course of RA. Rheumatoid arthritis, per se, is a cardiovascular (CV) risk factor as arterial hypertension, dyslipidemia and diabetes etc. Although the increased CV risk is acknowledged, limited attention is paid to detecting and managing CV comorbid conditions. Early identification, adequate CV risk management and ongoing monitoring of risk factors are mandatory to reduce the CV risk. Also, adequate control of arthritis disease activity is necessary to lower CV risk.
Collapse
|
41
|
Galesić K, Morović-Vergles J, Ljubanović D. [Renal changes in vasculitis: case report]. LIJECNICKI VJESNIK 2009; 131:4-9. [PMID: 19348348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Fifteen patients with vasculitis and renal manifestations have been analyzed. All patients had renal manifestation of vasculitis. Renal biopsy was performed in 13 patients: 6 patients had microscopic polyangiitis, 4 Wegener's granulomatosis, 2 microscopic polyangiitis limited to the kidneys and 3 polyarteritis nodosa. Renal biopsy was not performed in 2 patients. One patient had renal insufficiency and small kidneys and one patient had polyarteritis nodosa. The diagnosis of the polyarteritis nodosa in this last patient was made because of other clinical and laboratory data. Pauci-immune type of glomerulonephritis was found in 11 patients. The crescents, usually cellular, fibrocellular and rarely fibrotic, were present in 20-100% glomeruli. Renal insufficiency at baseline was present in 14 patients (creatinine 215-1224 micromol/L). Only one patient had borderline renal function when the diagnosis of vasculitis was made (creatinine 115 micromol/L). All patients with glomerulonephritis were treated with glucocorticosteroids and cyclophosphamide. Five patients with pulmonary manifestations of disease or advanced renal failure also were treated with plasmapheresis. Eight patients were treated by hemodyalisis. The complete or partial remission in the first year of the follow-up was reached in 9 patients, and 5 patients were treated by chronic dialysis due to chronic renal failure. One patient with Wegener's granulomatosis died after he developed toxic megacolon and postoperative sepsis.
Collapse
|
42
|
Morović-Vergles J, Salamon L. [Lupus nephritis]. REUMATIZAM 2009; 56:34-40. [PMID: 20429260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Systemic lupus erythematosus, an autoimmune disorder which predominantly affects young women, is frequently complicated by renal involvement. Lupus nephritis (LN) is characterized by immune-complex mediated glomerular and tubulointerstitial inflammation Ieading to chronic renal insufficiency in up to 30% affected patients. In patients with suspected lupus nephritis, renal biopsy may be used to confirm the diagnosis and determine appropriate therapy. The ISN/RPS classification of LN represents a significant advance over the 1982 WHO scheme. The treatment of lupus nephritis often consists of a period of intensive immunosuppressive therapy (induction therapy) followed by a period of less intensive maintenance therapy. The established treatment of lupus nephritis with cyclophosphamide and steroids has improved the outcome of LN but is burdened with significant adverse effects. Results of clinical studies showed that mycophenolate mofetil is equally effective with fewer toxic complications than standard therapy, but its long-term efficacy is not yet known. New therapeutic agents (biologic drugs) targeted to the pathogenetic mechanism of the disease are promissing improved efficacy with less toxicity. Despite recent advances, treatment of lupus nephritis remains a challenging clinical problem.
Collapse
|
43
|
Tomić M, Galesić K, Morović-Vergles J, Romić Z, Mikulić I. The role of endothelin-1 and nitric oxide in the pathogenesis of hypertension in diabetic patients. COLLEGIUM ANTROPOLOGICUM 2008; 32:93-98. [PMID: 18496905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The pathogenesis of renal hypertension has not yet been fully clarified. As the potential role of endothelin-1 (ET-1) and nitric oxide (NO) has been postulated, their concentrations were determined in plasma and urine of diabetic patients. The study included 30 diabetic patients (both IDDM and NIDDM) with initial or advanced diabetic nephropathy (decreased endogenous creatinine clearance, proteinuria) and 20 healthy control subjects. The correlation with blood pressure and other renal function parameters was monitored and compared with the control group. Also, the effect of ACE inhibitors (ACEI) on ET-1 and NO patterns was monitored in correlation with arterial hypertension. In diabetic patients that did not receive ACEI therapy, the increase in plasma ET-1 was associated with both systolic and diastolic blood pressure elevation, whereas in those administered ACEI the increase in plasma ET-1 was associated with a systolic blood pressure decline. In addition, the increase in plasma NO was accompanied by a statistically significant decline of both systolic and diastolic blood pressure in diabetic patients receiving ACEI.
Collapse
|
44
|
Morović-Vergles J. [Meloxicam--the balance of efficacy and safety]. REUMATIZAM 2008; 55:85-86. [PMID: 19024285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
NSAIDs remain the principal pharmacological agents used for symptom relief in patients with rheumatic disease. They represent the largest single group of drugs used worldwide. Given the large number of available NSAIDs, it is unsurprising that some differences exist among them with regard to mechanism of action, pharmacokinetics, and tolerability. How these differences affect the overall risks and benefits of treatment continues to be examined in clinical trials. Meloxicam is COX-2 selective NSAID with favourable gastrointestinal and thromboembolic safety profile.
Collapse
|
45
|
Grgurević I, Pejsa V, Morović-Vergles J, Dobrić I, Gasparović V, Tudorić N. Fatal toxic epidermal necrolysis and severe granulocytopenia following therapy with cefuroxime. ACTA DERMATOVENEROLOGICA CROATICA : ADC 2008; 16:133-137. [PMID: 18812062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Toxic epidermal necrolysis (TEN) is one of the most threatening adverse reactions to various drugs. No case of concomitant occurrence TEN and severe granulocytopenia following the treatment with cefuroxime has been reported to date. Herein we present a case of TEN that developed eighteen days of the initiation of cefuroxime axetil therapy for urinary tract infection in a 73-year-old woman with chronic renal failure and no previous history of allergic diathesis. The condition was associated with severe granulocytopenia and followed by gastrointestinal hemorrhage, severe sepsis and multiple organ failure syndrome development. Despite intensive medical treatment the patient died. The present report underlines the potential of cefuroxime to simultaneously induce life threatening adverse effects such as TEN and severe granulocytopenia. Further on, because the patient was also taking furosemide for chronic renal failure, the possible unfavorable interactions between the two drugs could be hypothesized. Therefore, awareness of the possible drug interaction is necessary, especially when given in conditions of their altered pharmacokinetics as in case of chronic renal failure.
Collapse
|
46
|
Morović-Vergles J. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?]. REUMATIZAM 2008; 55:70-72. [PMID: 19024280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
B cells play a critical role in the pathogenesis of rheumatoid arthritis. Recently, a number of biological agents that target B cells have been tested as therapies for these conditions. Of this group of agents, the first in clinical use has been rituximab, a chimeric monoclonal antibody that depletes B cells by binding to the CD20 cell-surface antigen. 25-40% of patients treated with a TNF inhibitor fail to achieve adequate response. A treatment response is inadequate if low disease activity or remission is not achieved. Treatment of patients with inadequate response to TNF inhibitors represents a challenge. What are the options? Switch to another anti-TNFalpha agent or initiate treatment with a biological agent with a different mechanism of action? In patients with persistent active disease despite anti-TNFalpha therapy, treatment with rituximab may be more effective than switching to another anti-TNFalpha.
Collapse
|
47
|
Morović-Vergles J. [Cardiovascular disorders in rheumatoid arthritis]. REUMATIZAM 2008; 55:53-56. [PMID: 19024275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease. Traditional cardiovascular risk factors (including male sex, family history for cardiovascular disease, age, dyslipidaemia, arterial hypertension, diabetes mellitus, smoking and obesity) do not adequately account for the extent of cardiovascular disease in RA. The pathogenesis of accelerated atherosclerosis in RA is not clear. Increasing evidence suggests a key role of inflammation in the onset and progression of atherosclerosis. Endothelial dysfunction represents the earliest manifestation of atherosclerosis. Hypertension prevalence in patients with RA is higher than that in the general population, It is attributable risk to the development of future cardiovascular events. Despite its serious complications, control of hypertension is far from adequate in the general population and even more so in rheumatoid arthritis patients.
Collapse
|
48
|
|
49
|
Grazio S, Morović-Vergles J. [Alendronate and vitamin D (Fosavance): persistence, adherence and importance of vitamin D]. REUMATIZAM 2007; 54:89-92. [PMID: 18351154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Persistence and adherence are major determinants of optimal results in the treatment of osteoporosis. In order to improve the efficacy of antiresorptive drugs, fewer demands on patients and better adherence were obtained with less frequent dosing schedule. Once-weekly and once-monthly oral bisphophonates showed equivalency with once daily medications. Comparison of persistence and adherence between weekly and monthly bisphosphonate regimens revealed conflicting results. In Croatia, persistence and adherence of weekly alendronate seem to be better than in other countries. In the light of compliance problems there is a need to assure adequate intake of vitamin D, because it is essential for prevention and treatment of osteoporosis and osteoporotic fractures. Vitamin D has other beneficial effects, particularly on neuromuscular performances. A high prevalence of vitamin D inadequacy was seen across all geographic regions. Weekly alendronate and vitamin D in one tablet provides proven fracture prevention at the spine and hip, and assure that patients receive a weekly dose of vitamin D.
Collapse
|
50
|
Morović-Vergles J, Grazio S. [Rational pharmacotherapeutic pain treatment in seronegative spondyloarthropathies]. REUMATIZAM 2007; 54:77-80. [PMID: 18351149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The aims of management in seronegative spondiloarthritides are to control pain and inflammation, maintain optimal mobility of spine and peripheral joints, restoration and preservation of functional ability, prevent contractures and deformities. Non-steroidal anti-inflammatory drugs are the basis of drug treatment. Numerous non-steroidal anti-inflammatory drugs have been shown to reduce pain and inflammation. Apart from non-steroidal anti-inflammatory drugs, in order to control the pain pure analgesics and weak opioids are the most often used drugs. In this paper is discussed use of these drugs in patients with seronegative spondyloarthritides.
Collapse
|